Description
Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC 50 of 91 nM.In VivoLy93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice. Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6J mice. Dosage: 100 mg/kg. Administration: I.G. (gavage) once daily for 7 days. Result: Significantly decreased the plasma SM levels compared with vehicle group. Animal Model: ApoE KO mice (eight-week-old). Dosage: 12.5 or 40 mg/kg. Administration: I.G. (gavage) once daily. Result: The levels of ALT and AST in the plasma of apoE KO mice did not show statistic changes when compared with the control group.Form:Solid